The FDA issued another round of warning letters to telehealth companies last week, and published them today alongside a warning to telehealth companies. But buried beneath the headlines is a signal that could be more important than the letters themselves: the agency appears to be focusing its fire on marketing practices, not on 503A compounding as a who…